Short-acting GHRH analogue evidence
Modified GRF(1-29) / 'CJC without DAC' vs Sermorelin
Sermorelin/native GHRH(1-29) has direct human endocrine evidence; exact tetrasubstituted Modified GRF lacks dedicated human clinical evidence. Do not.
At a glance
Modified GRF(1-29) / 'CJC without DAC'
Sermorelin
Human evidence
No dedicated peer-reviewed human clinical trial of the exact tetrasubstituted Modified GRF(1-29) / 'CJC-1295 without DAC' product was identified in this search. Related human studies of native GHRH(1-29), D-Ala2 analogues and CJC-1295 with DAC establish GHRH biology but are different molecules.
Native GHRH(1-29)/sermorelin has genuine human endocrine and diagnostic evidence. In a tiny 6-week study of older men, nightly GHRH increased nocturnal GH but did not significantly improve IGF-I or DEXA body composition.
Research focus
Growth-hormone axis research
Growth-hormone diagnostic/deficiency research
Regulatory status
No specific FDA-approved product named 'CJC-1295 without DAC' was identified.
Historical FDA marketing approval existed for Geref (sermorelin acetate); this does not confer approval on generic research-market sermorelin.
Route / formulation
Chemical identity should be confirmed because 'without DAC' is often used loosely for modified GRF(1-29).
Current authorization and product quality must be checked by jurisdiction/product.
No direct head-to-head clinical outcome trial Sermorelin/native GHRH(1-29) has direct human endocrine evidence; exact tetrasubstituted Modified GRF lacks dedicated human clinical evidence. Do not transfer dose/PK directly.